secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001558370-23-019016
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Q3 loss from ops $(10.3)M; cash $24M; AP-SA02 and AP-PA02 enrollment accelerating
--------------------------------------------------------------------------------

- Grant revenue $1.2M (vs $1.3M); R&D $8.0M (vs $8.4M); G&A $3.6M (vs $1.6M) due to one-time financing costs.
- Loss from operations widened to $(10.3)M from $(8.6)M YoY.
- Cash $24.0M as of Sept 30 vs $14.9M Dec 31, 2022; $25M credit agreement with Innoviva signed July 2023.
- Phase 2a diSArm (AP-SA02) and Phase 2 Tailwind (AP-PA02) enrollment accelerating; expects Phase 2 diSArm completion in 2024.
- Shares outstanding ~36.1M as of Nov 14, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000155837023019016/0001558370-23-019016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000155837023019016/armp-20231114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer